Background
==========

Maintenance of the level of excitability of neurons in the central nervous system is essential to maintain homeostasis. This balance is achieved through the regulation of excitatory and inhibitory neurotransmitters. Any change in this balance can lead to hyperexcitable cells and subsequently to seizures. Possible mechanisms that may contribute to hyperexcitability include changes in ion homeostasis, ion pumps, hormones, and changes in levels/efficiency of neurotransmitters. Of these neurotransmitters, the regulation of neuron excitability by γ-aminobutyric acid (GABA), the predominant inhibitory neurotransmitter, is especially required to prevent hyperexcitability, and thus prevent seizures. Epileptogenicity is characterized by chronic hypersensitivity to sensory stimuli and thus is dependent upon the amount of hyperexcitability expressed by neurons. In a homeostatic brain, the GABAergic system plays an integral role in lowering the threshold required for an excitatory stimulus of neurons. GABA, released from presynaptic neurons, binds to the ionotropic GABA~A~ receptor, allowing chloride influx and resulting in the hyperpolarization of the postsynaptic neuron. Any perturbation of the GABAergic system, therefore, could contribute to excitability of the neuron and seizure induction.

Synthesis of GABA by glutamic acid decarboxylase (GAD) is critical for maintenance of GABA-mediated inhibition and regulating levels of excitability \[[@B1],[@B2]\]. GAD exists in two isoforms, GAD65 and GAD67, both encoded by different genes \[[@B3]\]. Both enzymes require the coenzyme pyridoxal phosphate, with GAD65 having a more significant requirement \[[@B2],[@B4]\] for regulation of activity. GAD65 appears to be an apoenzyme (lacking the coenzyme), but once the coenzyme is present, exhibits a significantly higher enzymatic activity than GAD67 \[[@B5]\]. GAD67 exists mainly as a holoenzyme in the cytoplasm \[[@B5]\]; regulation of this enzyme appears to be more associated with gene-level expression \[[@B2]\]. There is also abundant evidence that GAD65 expression can also be affected at the gene-level \[[@B3],[@B6],[@B7]\].

As GAD is the rate-limiting enzyme for GABA synthesis, perturbation of GAD activity would lead to GABA depletion and, subsequently, to an increase in seizure susceptibility. Isoniazid, a widely used drug to combat tuberculosis, is also and effective GAD inhibitor, leading to the rapid depletion of GABA \[[@B8]-[@B10]\]. Large doses of isoniazid cause severe fatal seizures in experimental animals \[[@B11]\]. We have previously reported that the threshold dose for induction of seizures in mice is 200 mg kg^-1^\[[@B12]\], and that doses higher than 200 mg kg^-1^ induce seizures of short duration and latency. Isoniazid is not GAD-specific, but also inhibits other enzymes required pyridoxal phosphate as a coenzyme. When mice are administered pyridoxal phosphate 15 min prior to treatment with isoniazid, we found that the threshold shifted to 250 mg kg^-1^ and that doses as high as 350 mg kg^-1^ delayed seizure onset and severity \[[@B12]\]. The data suggest that isoniazid likely competes for the pyridoxal phosphate-binding site on GAD.

Seizures can be induced by the administration of kianic acid (KA), a glutamate analogue. Treatment with KA can manifest in the GABAergic system through loss of a subpopulation of GAD-positive neurons, leading to limbic seizures \[[@B13]\]. Limbic seizures mostly affect the hippocampus, dentate gyrus, and entorhinal cortex \[[@B14],[@B15]\]. Previously, we have reported that the threshold dose for KA is 10 mg kg^-1^\[[@B12]\], with doses at or above 30 mg kg^-1^ inducing fatal seizures. Taken together, both isoniazid and KA appear to negatively regulate the GABAergic system, either directly through hyperexcitability or indirectly through depletion of GABA), resulting in seizures.

We are interested, therefore, in mechanisms by which we may positively influence the GABAergic system to form a compensatory mechanism by which seizure onset and severity may be reduced. To this end, we have found that taurine may be beneficial and may work through the GABAergic system via the GABA~A~ receptor. We have previously reported that chronic supplementation of taurine in drinking water to mice increases brain excitability mainly through alterations in the inhibitory GABAergic system \[[@B12]-[@B15]\]. Taurine, 2-aminoethanesulfonic acid, concentrations are high in the CNS \[[@B16]\], especially in the neonate \[[@B17]-[@B19]\], but drop during development. Others and our laboratories have demonstrated a relationship between taurine and the GABAergic system. For example, there are brain region-specific levels of GAD and that GAD expression (both isoforms) is elevated in mice chronically fed taurine \[[@B12],[@B18]\]. Taurine is an agonist of the GABA~A~ receptor \[[@B20],[@B21]\] and activates chloride influx into postsynaptic neurons via this receptor \[[@B19]\]. Chronic administration of taurine to mice leads to a reduction in the β2/β3 GABA~A~ subunits \[[@B19]\]. Using a sub-threshold dose of isoniazid coupled with sub-threshold dose of KA, we have demonstrated that mice undergo seizures with a short latency and duration, and this combination was lethal in a majority of animals \[[@B12]\]. In mice chronically administered taurine prior to isoniazid/KA treatment, we demonstrated that taurine was effective in reducing the severity of seizures as latency was significantly increased and mortality significantly decreased \[[@B12]\].

Together, our data suggest that taurine interacts directly with the GABAergic system, likely via the GABA~A~ receptor. To further test this hypothesis, here we used a potent GABA~A~ antagonist, picrotoxin. Picrotoxin binds to the β2/β3 subunits of the GABA~A~ receptor, the same subunits demonstrated to be reduced by chronic exposure to taurine. Here we describe the efficacy of taurine in decreasing picrotoxin-induced seizures.

Methods
=======

Pharmacological agents
----------------------

Picrotoxin was dissolved in isotonic saline at 3 mg/ml. All mice used in this study were two-month-old FVB/NJ males and all injections were subcutaneous. For taurine-fed mice, taurine was dissolved in water at 0.05%, and this solution was made available to the mice in place of drinking water for 4 weeks beginning at 4 weeks of age. For taurine-injected mice, mice were administered 43 mg kg^-1^ subcutaneous 15 min prior to picrotoxin treatment. All mice were housed in groups of three in a pathogen-free room maintained on a 12 hr light/dark cycle and given food and water ad libitum. All procedures were approved by the Institutional Animal Care and Use Committee of the College of Staten Island/CUNY and were in conformity with National Institutes of Health Guidelines.

Behavioral analysis
-------------------

Animals were put into individual cages the day before the experiments. After treatment, animals were transferred to clear animal cages and videotaped for 4 h. Seizures were scored by two independent observers who were unaware of the treatment. The observers were asked to look for the following stereotypical behaviors: motionless stare, rearing and falling, clonic convulsions, tonic-clonic seizures (status epilepticus) and death. The occurrence of these behaviors, the time from injection to initiation of the behavior (latency) and the duration of the convulsions are measures of seizure severity. Saline-injected animals did not show any seizure behavior.

Results
=======

Behavioral analysis
-------------------

Following picrotoxin injection, control mice exhibited a short latency period to the onset of seizures (Figure [1](#F1){ref-type="fig"}). The duration of these seizures were short, and in two thirds of the control mice, seizures were fatal. In the taurine-injected mice, the latency was significantly longer (P\<0.001) as were the durations (Figure [1](#F1){ref-type="fig"}). Further, mortality rate in these mice were also significantly less (12% p\<0.001), suggesting that taurine was protective of the effects of picrotoxin via the GABA~A~ channel. Similarly, chronic administration of taurine also significantly reduced the effects of picrotoxin, as the latency and duration of seizures were also longer (P\<0.05) (Figure [1](#F1){ref-type="fig"}). Chronic administration also significantly improved survivability compared to controls. The data suggests that taurine may act either at the picrotoxin-binding site or at the GABA binding site of the GABA~A~ receptor. Alternatively, taurine could mediate it protective effects against picrotoxin-induced seizures through activation of taurine receptor \[[@B22]\].

![**Latency to seizures** Two-month-old male mice treated with 5 mg kg^-1^ picrotoxin presented with short latency periods (control) that were also of short duration. Seizures were nearly always fatal (66%). Treatment with taurine significantly increased latency and duration, whether route of administration was injection 15 min prior to picrotoxin injection (Tau-Inj) or chronic feeding of taurine (Tau-Fed). In both cases, taurine significantly improved survivability (P\<0.05).](1423-0127-17-S1-S14-1){#F1}

Discussion
==========

Picrotoxin is a potent antagonist of the GABA~A~ receptor. Binding of picrotoxin to β2/β3 subunits of the receptor effectively blocks the chloride channel, resulting in a post-synaptic neuron that is more easily excitable and prone to hyperexcitability. As such, picrotoxin-induced toxicity is epileptogenic \[[@B10],[@B23]-[@B25]\]. There is compelling evidence that taurine interacts with the GABAergic system via the GABA~A~ receptor \[[@B19],[@B25]-[@B30]\]. Taurine as also been shown to activate a taurine receptor \[[@B22]\], but the molecular identity of this receptor has not been fully characterized. Chronic taurine administration results in improved chloride conductance while selective depression of β2/β3 subunits expression occurs \[[@B19]\], the same subunits to which picrotoxin binds \[[@B31]\]. Taurine therefore maintains the integrity of the chloride channel via binding to the receptor. The site to which taurine binds, however, remains elusive. The data here suggests that taurine may bind to the GABA binding site of the receptor, keeping the channel open. In both taurine-fed and injected mice, hyperexcitability was diminished, as demonstrated by the longer latency and duration of seizures. If taurine binds to the GABA binding site, the receptor would remain open as long as taurine was present. This scenario could explain the acute taurine administration data: taurine binds to the GABA~A~ receptor and allows the cells to become hyperpolarized and thus resistant to picrotoxin-induced seizures. For the chronically fed taurine animals, the taurine would most likely be sequestered by neurons, forming intracellular pools of taurine that would primarily be used for osmoregulation of the neurons \[[@B32]-[@B36]\]. In the taurine-fed mice, the administration of picrotoxin could signal a release of intracellular stores of taurine, which could bind to the GABA binding site and open the channels. An alternative explanation of these findings would be the activation of the taurine receptor \[[@B22]\] or a synergistic effect between the GABA~A~ and the taurine receptor could explain the selective resistance to mice to picrotoxin-induced seizures.

Conclusions
===========

Taurine administration may interact with the GABAergic system at two points. First, taurine may interact at the level of the enzyme GAD. Chronic administration of taurine to mice leads to an increase in GAD levels (both isoforms) in GABAergic neurons. This in turn leads to an increased expression in GABA in presynaptic neurons. Second, taurine interacts at the level of the GABA~A~ receptor. Binding of taurine to the receptor increases chloride influx into the cell, hyperpolarizing the postsynaptic neuron to reduce excitability. Chronic administration of taurine also influences the expression of the β2/β3 subunits of the GABA~A~ receptor, which in turn may influence the expression of GAD in the presynaptic neuron via a feedback mechanism. The data from this and previous studies provide strong evidence for the neuroprotective role of taurine in the GABAergic system.

Competing interests
===================

The authors have no competing interests.

Authors\' contributions
=======================

WJL participated in the design of the study, and drafted the manuscript. AEI conceived of the study, performed the statistical analysis and participated in its design and coordination as well as edited the manuscript. Alexandra Marsillo video recorded seizures and helped in recording data of seizures. All authors read and approved the final manuscript.

Acknowledgements
================

The authors wish to thank Alina Kogan and Elizabeth Che analyzing videos of seizures, and the staff of the College of Staten Island's vivarium. The authors also wish to thank the organizing committee of the 17^th^ International Taurine Meeting in which preliminary data were presented. Support for this project comes from FRAXA and PSC-CUNY to AEI.

This article has been published as part as part of *Journal of Biomedical Science* Volume 17 Supplement 1, 2010: Proceedings of the 17th International Meeting of Taurine. The full contents of the supplement are available online at <http://www.jbiomedsci.com/supplements/17/S1>.
